Facebook
Twitter
LinkedIn
Forward
Evolving Evidence for Targeted Therapies: A Digital Journey Towards Individualized Management of Alopecia Areata Patients
Alopecia areata (AA) is an autoimmune disease that results in hair loss on the scalp and body. Currently,
there is no FDA approved treatment for alopecia areata, challenging clinicians to find effective
treatments in practice. However, recent findings have furthered understanding of AA, including the
targeting of specific immunologic pathways. Multiple clinical studies are underway investigating the use
of Janus kinase (JAK) and TEC-family kinase inhibitors for treatment of moderate-to-severe AA.
Additionally, is critical that clinicians are aware of the psychosocial burden and address these
psychological effects when developing a personalized treatment plan utilizing these newer therapies.
This activity will take clinicians on a digital journey to increase knowledge and competence surrounding
the burden of disease and pathogenesis of AA, as well as review emerging therapeutic options to be
used in a patient-centered treatment approach.
Target Audience
This activity is designed to meet the dermatologists who are involved in the care and treatment of patients with alopecia areata.
Learning Objectives
- Summarize the burden of disease for AA patients including psychosocial and medical comorbidities
- Review signaling pathways involved in the pathogenesis of alopecia areata
- Interpret clinical safety and efficacy data, as well as mechanisms of action, for emerging treatments of alopecia areata
- Apply knowledge of new and emerging therapies for optimal patient selection and treatment plan design
a. “What is Alopecia Areata?”
2. “Clinical Manifestation of AA”
a. “Clinical Features of Alopecia Areata”
b. “Burden of Disease and Multidisciplinary Care”
3. “Pathogenesis” Page
a. “AA Disease Pathogenesis – What is the JAK-STAT Pathway?”
b. “JAK Inhibitors: Examining the Mechanism of Action”
4. “Current Treatments”
a. “Current Treatment Recommendations for AA Patients”
5. “New Targets for Treatment”
a. “Emerging Therapeutics for AA – Examining Safety and Efficacy”
b. “Interactive Alopecia Areata Therapeutic Pipeline”
6. “Closing Remarks”
a. “What Can Clinicians Expect to See in the Near Future?”
b. “Will JAK Inhibitors Be Used to Treat Adolescent Patients with AA?”
Brittany Craiglow, MD
Associate Adjunct Professor
Yale School of Medicine
New Haven, CT
Maria Hordinsky, MD
Professor and Chair
Department of Dermatology
University of Minnesota
Minneapolis, MN
Brett King, MD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, CT
Disclosure of Conflicts of Interest
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Name of Faculty or Presenter | Reported Financial Relationship |
Brittany Craiglow, MD | Advisory Boards: Eli Lilly, Pfizer, Regeneron (Disease States: Alopecia Areata, Atopic Dermatitis) Consulting: Eli Lilly, Pfizer (Disease State: Alopecia Areata) Speakers Bureaus': Eli Lilly, Pfizer, Regeneron, Sanofi-Genzyme (Disease States: Atopic Dermatitis, Psoriasis) |
Maria Hordinsky, MD | Consulting: Pulse Bioscience, Cerave Hair & Scalp (Advisory Board), Arcutis Biotherapeutics, Inc. Researcher: Pfizer, Eli Lilly, Concer Royalties or Patient Beneficiary: McGraw Hill, UptoDate |
Brett King, MD | Consultant: AbbVie, AltruBio, Inc., Almirall, AnaptysBio, Arena Pharmaceuticals, Bionz Therapeutics, Bristol-Myers Squibb, Concert Pharmaceuticals, Inc., Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi-Genzyme, TWi Biotechnology In, and Viela Bio (Disease States: Alopecia Areata, Atopic Dermatitis, Vitiligo) Researcher: Clinical trial investigator for AnaptysBio, Arena Pharmaceuticals, Concert Pharmaceuticals, Inc, Eli Lilly and Company, Pfizer Inc (Disease State: Alopecia Areata) Speakers Bureaus: AbbVie, Incyte, Leo Pharma, Pfizer Inc, Regeneron and Sanofi Genzyme (Disease Date: Atopic Dermatitis)
|
| Dorothy Caputi, MA, BNS, RN-CE Director of Accreditations | Nothing to disclose |
| Michele Bierlarski, RN-Nurse Reviewer | Nothing to disclose |
| LivDerm Planners and Reviewers | Nothing to disclose |
| AKH Planners and Reviewers | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
AKH Privacy Policy link: https://akhcme.com/akhcme/pages/privacy
Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LivDerm
Estimated time to complete activity: 1 hour
Commercial Support
This activity is supported by an educational grant from Pfizer.
Physician Continuing Medical Education
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
1.0 ANCC contact hour
Internet
Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.
Hardware/Software Requirements
A computer or device with an internet connection.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.